Nerac

Information That Drives Innovation

We’re here to help with your research needs
+1 860 872 7000
Customer Access
  • Home
  • What We Do
    • Innovation Insights and Consulting Practice
    • Regulatory
    • Medical Device and Life Sciences
    • Technology Scouting and Innovation
    • Market Research
    • Intellectual Property
    • Commercialization Services for TTOs and Start-Ups
    • Critical Updates
  • Who We Serve
  • How to Engage
  • Why Nerac?
  • Meet our Team
    • Leadership Team
    • Our Analysts
    • Our Partners
  • Nerac Insights and Publications
    • Articles
    • Case Studies
    • Press Room
    • Videos
    • Webcasts
    • White Papers
  • Contact Us
You are here: Home / Nerac Insights / Articles / Risk Assessment and the Value of a Comprehensive Post-Market Surveillance Program

Risk Assessment and the Value of a Comprehensive Post-Market Surveillance Program

Facebook0
Google+0
LinkedIn0
Twitter0
By Carol Young, Nerac Analyst,
Originally Published: January 20, 2016

Risk Assessment plays an important role in getting products approved and placed on market, and while post market surveillance is not a new requirement, it is now clear that the notified bodies have placed an increased focus in this area and expect it to be an essential component of the overall clinical evaluation of marketed devices. Make sure you are covered here.

Want to read the rest of the article? Fill out the form to download: Risk Assessment and the Value of a Comprehensive Post-Market Surveillance Program
Get Download Link

Related Posts

  • Are Your Devices State-of-the-Art?
    76
    By Ron Sills, Nerac Analyst Originally Published: September 29th, 2014 The European Union’s Council Directive  93/42/EEC concerning medical devices  contains the essential requirements to be met by medical device manufacturers in order to market their products in the 28 member countries.  A technical file for Class IIa and IIb devices, or a design dossier for…
    Tags: devices, medical, products, market, essential, device, read, analyst, originally, nerac
  • Full Speed Ahead: Navigating the New European Medical Device Regulation
    58
    By Robert Zott, Director of Advisory Services Originally Published: July 18, 2018 The publication of the new Medical Device Regulation (MDR) 2017/745 in the European Journal, with its entry into force on May 25, 2017, marks the end of an eight-year period of controversy, and the beginning of a three-year transition to the most sweeping…
    Tags: device, medical, published, bodies, read, article, originally, risk, form, devices
  • The New Post-Market Surveillance Regulations for Europe, Part 2: Serious Incidents Get A Serious Overhaul.
    56
    By Robert Zott, Director of Advisory Services Development Originally published November 13, 2018 There is now 1 year, 6 months and 20 days until the application date upon which the new European Medical Device Regulation (MDR) goes into effect. For those charged with the task of upgrading systems for MDR compliance, that’s 567 days or…
    Tags: article, published, originally, clinical, bodies, evaluation, notified, post-market, read, surveillance
  • Case Studies
  • White Papers
  • Webcasts
  • Articles
    • Nerac Strategist
    • Energy
    • Food & Nutrition
    • Intellectual Property
    • Regulatory
    • Technology & Innovation
    • Medical Device & Healthcare
    • Pharmaceutical
    • Engineering
    • Market Research
    • Critical Alerts
    • Chemistry/Advanced Materials
  • Press Room

Click here to learn more about….

3d printing advanced materials aerospace Ask Kevin Videos biotech CFDA clinical literature evaluations commercialization strategies competitive intelligence conflict minerals Disruptive Technologies emerging markets energy EU MDR FDA food Industry 4.0 innovation Inspiring Next intellectual property intellectual property strategies IP market analysis market research medical device medical devices nerac Nerac client questions Nerac Strategist notified body audit open innovation Order 650 patenting strategies patent landscape pharmaceutical Post-Market Surveillance R&D regulatory regulatory compliance Robert Beinstein Rosemarie Szostak specialty chemicals Sustainable Development Goals technology scouting XcellR8
  • Facebook
  • Google+
  • Linkedin
  • RSS
  • Twitter
  • YouTube
  • Career Opportunities

Copyright © 2021 Nerac · One Technology Drive · Tolland, CT 06084 · 1.860.872.7000

Sign Up for the Nerac Strategist

Like what you see? Sign up here to receive the Nerac Strategist newsletter, a compilation of analyst insights on rapidly developing industry issues, compliance challenges and commercial opportunities!
  • This field is for validation purposes and should be left unchanged.